CytoMed Therapeutics Limited most recently reported annual revenue of $0, a net loss of $4.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
CytoMed Therapeutics Limited: net profit was positive in 0 of 7 reported years; operating margin moved from -624.5% to -1416.0%, a shift of -791.5 percentage points; the most recent year shows a net loss of $4.0M.
Income Statement — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$1.0M
$0
$0
Operating Expenses
$1.0M
$1.0M
$1.0M
$3.0M
$2.0M
$3.0M
$5.0M
Operating Profit
$-1.0M
$-1.0M
$-1.0M
$-2.0M
$-2.0M
$-3.0M
$-5.0M
Operating Margin
0.0%
0.0%
0.0%
-624.5%
-310.2%
-4504.3%
-1416.0%
Other Income
$0
$-1.0M
$-1.0M
$-1.0M
$-3.0M
$1.0M
$1.0M
Interest
$0
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$-1.0M
$-2.0M
$-2.0M
$-3.0M
$-4.0M
$-3.0M
$-4.0M
Tax
$0
$0
$0
$-50,000
$-20,000
$2.1M
$0
Net Profit
$-1.0M
$-2.0M
$-2.0M
$-3.0M
$-4.0M
$-3.0M
$-4.0M
EPS
$-0.15
$-0.33
$-0.30
$-0.40
$-0.38
$-0.22
$-0.33
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Jun '23
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Jun '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$2.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$2.0M
$1.0M
$1.0M
$1.0M
$3.0M
$2.0M
Operating Profit
$-2.0M
$0
$0
$-1.0M
$-1.0M
$-1.0M
$-2.0M
$-1.0M
$-1.0M
$-1.0M
$-2.0M
$-2.0M
Operating Margin
-1107.5%
-390.9%
-390.9%
-473.3%
-473.3%
-366.3%
-2348.7%
-483.0%
-483.0%
-322.4%
-1403.1%
-1272.9%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$-2.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-2.0M
$-2.0M
Tax
$0
$-30,000
$-60,000
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Profit
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-1.0M
$-2.0M
$-2.0M
EPS
$-0.19
$-0.09
$-0.09
$-0.05
$-0.09
$-0.06
$-0.13
$-0.10
$-0.10
$-0.07
$-0.14
$-0.15
Over the 7 years reported for CytoMed Therapeutics Limited, borrowings decreased from $1.0M in 2019 to $0 in 2025, cash stood at $2.0M in the latest year, shareholders' equity was $25.0M, current assets covered current liabilities 4.00 times.
Balance Sheet — 7 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
Total Assets
$3.0M
$4.0M
$6.0M
$5.0M
$12.0M
$10.0M
$8.0M
Current Assets
$1.0M
$1.0M
$3.0M
$3.0M
$10.0M
$6.0M
$4.0M
Cash
$0
$1.0M
$3.0M
$2.0M
$9.0M
$5.0M
$2.0M
Inventory
$0
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
Receivables
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
$2.0M
$2.0M
$3.0M
$2.0M
$2.0M
$3.0M
$4.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$0
$0
$0
$0
Other Assets
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$1.0M
$3.0M
$3.0M
$5.0M
$1.0M
$1.0M
$1.0M
Current Liabilities
$0
$3.0M
$3.0M
$4.0M
$1.0M
$1.0M
$1.0M
Borrowings
$1.0M
$3.0M
$3.0M
$4.0M
$0
$0
$0
Other Liabilities
$0
$0
$0
$0
$1.0M
$1.0M
$1.0M
Equity
$3.0M
$4.0M
$7.0M
$9.0M
$24.0M
$24.0M
$25.0M
Reserves
$2.0M
$0
$3.0M
$1.0M
$11.0M
$9.0M
$7.0M
For CytoMed Therapeutics Limited, operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $4.0M; free cash flow was positive in 0 of 7 years.
What is CytoMed Therapeutics Limited's annual revenue?
CytoMed Therapeutics Limited (GDTC) reported annual revenue of $0 in its most recent fiscal year.
What is CytoMed Therapeutics Limited's net profit?
CytoMed Therapeutics Limited (GDTC) reported a net loss of $4.0M in its most recent fiscal year.
What is GDTC EV/EBITDA?
CytoMed Therapeutics Limited's enterprise value to EBITDA (EV/EBITDA) ratio is -2.11. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.